Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Liabilities and Shareholders Equity (2016 - 2026)

Standard Biotools has reported Liabilities and Shareholders Equity over the past 16 years, most recently at $567.8 million for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity fell 7.28% to $567.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.2 billion through Dec 2025, down 19.29% year-over-year, with the annual reading at $567.8 million for FY2025, 7.28% down from the prior year.
  • Liabilities and Shareholders Equity was $567.8 million for Q4 2025 at Standard Biotools, up from $539.6 million in the prior quarter.
  • Over five years, Liabilities and Shareholders Equity peaked at $777.7 million in Q1 2024 and troughed at $271.9 million in Q1 2022.
  • The 5-year median for Liabilities and Shareholders Equity is $402.6 million (2022), against an average of $454.2 million.
  • Year-over-year, Liabilities and Shareholders Equity soared 109.24% in 2024 and then fell 25.47% in 2025.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $275.2 million in 2021, then skyrocketed by 41.82% to $390.3 million in 2022, then fell by 17.23% to $323.1 million in 2023, then skyrocketed by 89.54% to $612.3 million in 2024, then decreased by 7.28% to $567.8 million in 2025.
  • Per Business Quant, the three most recent readings for LAB's Liabilities and Shareholders Equity are $567.8 million (Q4 2025), $539.6 million (Q3 2025), and $557.0 million (Q2 2025).